Curevo Vaccine

Curevo Vaccine is a clinical-stage biotechnology company based in Bothell, WA, focused on developing next-generation non-mRNA vaccines with improved tolerability. Its lead candidate is amezosvatein, an adjuvanted subunit shingles vaccine that reduced side effects by more than half in Phase 2 trials; the company agreed to be acquired by Eli Lilly for $1.5 billion.